Skip to content

Getting to Zero—Join the Movement!

  • Chad Cipiti

By Colleen Daniels Tuberculosis (TB), a 40,000-year-old disease, still devastates communities although it has been preventable—and curable—for decades. In 2010, the World Health Organization (WHO) reported 8.8 million TB cases—1.4 million of them fatal—worldwide. TB is the leading cause of…

Read more

TAGline Fall 2012

  • Chad Cipiti

TAG at 20 – Part II: On a Darkling Plain—The Years of Despair; Only Stronger U.S. Leadership Can End the AIDS Epidemic; Cure-Related Research at AIDS 2012; The Future of TB in the United States: Going, or Growing?; Getting to Zero—Join the Movement!; GeneXpert Rapid TB Test Price Reduced in Historic Agreement

Read more

Mark Harrington Tribute to Médecins Sans Frontières (MSF)

  • Dorrit Walsh

In 2012, the Fulbright Association presented its J. William Fulbright Prize for International Understanding to Médecins Sans Frontières (MSF); the first time this was awarded to an organization, not an individual. Treatment Action Group’s executive director, Mark Harrington, delivered this…

Read more

HIV i-Base/Treatment Action Group 2012 Pipeline Report Reveals Deep Gaps between Scientific Promise and Program Delivery

  • Chad Cipiti

On the eve of the XIX International AIDS Conference in Washington, D.C., a new report by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) reveals the deepening gulf between new scientific advances that make it possible to prevent, treat, and in some cases cure people living with HIV, hepatitis C virus (HCV), and tuberculosis (TB), and access to these where they are most needed.

Read more

2012 Pipeline Report

  • Chad Cipiti

HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development By Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan.

Read more

TAG and the TB CAB Send Open Letter to Otsuka

  • Chad Cipiti

TAG and the TB CAB send open letter to Otsuka to expedite plans to develop a pre-approval access program for delamanid for patients in urgent need, determine if delamanid is safe to use with bedaquiline, and develop the drug for pediatric use as rapidly and safely as possible.

Read more

TAG and TB CAB Issue Open Letter to Janssen

  • Chad Cipiti

TAG and TB CAB issue an open letter to Janssen, bedaquiline’s sponsor, about the need to accelerate pediatric research, to determine the safety of using bedaquiline and delamanid together, and to support Janssen’s compassionate use program to provide access to bedaquiline for people in urgent need in places where the drug has not yet been approved.

Read more
Back To Top